Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
Syndax Pharmaceuticals (SNDX) has scheduled its first quarter 2025 financial results announcement and business update for Monday, May 5, 2025. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day.
Investors and interested parties can access the webcast through the Events & Presentations page in the Investors section of Syndax's website. Alternative access is available via phone using the Conference ID: Syndax1Q25, with domestic dial-in at 800-590-8290 and international at 240-690-8800.
A replay of the conference call will be available on the company's website approximately 24 hours after the event and will remain accessible for 90 days.
Syndax Pharmaceuticals (SNDX) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per lunedì 5 maggio 2025. La società terrà una conference call e una diretta audio webcast alle 16:30 ET dello stesso giorno.
Investitori e parti interessate potranno accedere alla webcast tramite la pagina Eventi e Presentazioni nella sezione Investitori del sito web di Syndax. È disponibile un accesso alternativo telefonico utilizzando il Conference ID: Syndax1Q25, con numero nazionale 800-590-8290 e internazionale 240-690-8800.
La registrazione della conference call sarà disponibile sul sito web della società circa 24 ore dopo l'evento e resterà accessibile per 90 giorni.
Syndax Pharmaceuticals (SNDX) ha programado el anuncio de los resultados financieros del primer trimestre de 2025 y una actualización empresarial para el lunes 5 de mayo de 2025. La compañía realizará una conferencia telefónica y una transmisión en vivo por audio a las 4:30 p.m. ET ese mismo día.
Los inversores y partes interesadas pueden acceder a la transmisión a través de la página de Eventos y Presentaciones en la sección de Inversores del sitio web de Syndax. También hay acceso alternativo por teléfono usando el ID de conferencia: Syndax1Q25, con número nacional 800-590-8290 y número internacional 240-690-8800.
La repetición de la conferencia estará disponible en el sitio web de la compañía aproximadamente 24 horas después del evento y permanecerá accesible durante 90 días.
Syndax Pharmaceuticals (SNDX)는 2025년 1분기 재무 실적 발표 및 사업 업데이트를 2025년 5월 5일 월요일에 예정하고 있습니다. 회사는 같은 날 오후 4시 30분(동부 시간)에 컨퍼런스 콜과 라이브 오디오 웹캐스트를 진행할 예정입니다.
투자자 및 관심 있는 분들은 Syndax 웹사이트 투자자 섹션의 이벤트 및 프레젠테이션 페이지를 통해 웹캐스트에 접속할 수 있습니다. 전화 접속도 가능하며, 컨퍼런스 ID는 Syndax1Q25이고 국내 전화번호는 800-590-8290, 국제 전화번호는 240-690-8800입니다.
컨퍼런스 콜 녹음은 행사 약 24시간 후 회사 웹사이트에서 제공되며 90일 동안 이용할 수 있습니다.
Syndax Pharmaceuticals (SNDX) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 et une mise à jour commerciale pour le lundi 5 mai 2025. La société organisera une conférence téléphonique et une diffusion audio en direct à 16h30 ET le même jour.
Les investisseurs et parties intéressées peuvent accéder à la diffusion via la page Événements et Présentations dans la section Investisseurs du site web de Syndax. Un accès alternatif est disponible par téléphone avec l'ID de conférence : Syndax1Q25, avec un numéro national au 800-590-8290 et un numéro international au 240-690-8800.
Le replay de la conférence téléphonique sera disponible sur le site de la société environ 24 heures après l'événement et restera accessible pendant 90 jours.
Syndax Pharmaceuticals (SNDX) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 sowie ein Unternehmensupdate für Montag, den 5. Mai 2025 geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Live-Audio-Webcast veranstalten.
Investoren und Interessierte können den Webcast über die Seite Veranstaltungen & Präsentationen im Investor-Bereich der Syndax-Website abrufen. Alternativ ist der Zugang telefonisch mit der Konferenz-ID: Syndax1Q25 möglich, mit nationaler Einwahl unter 800-590-8290 und international unter 240-690-8800.
Eine Aufzeichnung der Telefonkonferenz wird etwa 24 Stunden nach der Veranstaltung auf der Website des Unternehmens verfügbar sein und für 90 Tage zugänglich bleiben.
- None.
- None.
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Company's financial results and provide a business update.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax1Q25
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-1q25.open-exchange.net/registration
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When will Syndax Pharmaceuticals (SNDX) release Q1 2025 earnings?
How can investors access SNDX's Q1 2025 earnings call?
How long will SNDX's Q1 2025 earnings call replay be available?
What is the conference ID for Syndax's Q1 2025 earnings call?
